

**To the Editor,  
World Journal of Gastroenterology**

**Dear Sir**

Thank you very much for the opportunity to revise manuscript 6444 on pancreatic cancer, with the previous title "Survival and Quality of life (QoL) in patients with pancreatic cancer". The title is now altered, see below.

The constructive criticism of reviewer 00186066 generated a major revision, including the following changes in the manuscript

1. New title: Pancreatic cancer - improved care achievable
2. Typographic errors are corrected
3. Improved "flow" of the manuscript: Several sections are reorganized. All text, focusing on one issue is put together, avoiding repetitions; ex: The paragraph on multidisciplinary approach on page 8 in the first manuscript, is cut, and built together with other aspects of the same issue, now written at page 9 under the correct subheading. Also different aspects of the section "treatment" are rewritten, focusing on improved logical progression in the manuscript. Finally, evidence based medicine is no longer a separate section.
4. Biomarkers are dealt with in greater detail (page 8), and Charis publication in Gastroenterology is quoted (ref 9) during the description of pathogenesis. But adrenomedullin can so far not be presented as a biomarker in my opinion – and ref 9 is not quoted in the Biomarker section.
5. Reviewers comment: "Presentation of surgical and chemotherapy data can be more informative in tabular form". My response has been to put core data on neoadjuvant chemotherapy versus up-front surgery together in table 2, and the algorithmic flow-chart in figure 1 is revised accordingly.
6. A separate section on Quality of life is included at page 14.
7. Finally a paragraph focusing on future development is added.

Please reconsider the revised version of manuscript 6444.

Oslo 26<sup>th</sup> December 2013

Yours sincerely

Trond Buanes